Inhibition of AKT has previously been demonstrated to increase proliferation and apoptosis of CML LSCs but it also impairs maintenance, self-renewal and quiescence of normal HSCs, making it a difficult target [46, 47]. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.